Goodwill and Intangible Assets, Net (Tables)

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of finite-lived intangible assets

As of March 31, 2019 and December 31, 2018, our identifiable intangible assets consisted of the following (in thousands):

	March 31, 2019								December 31, 2018
			Accumulated		Cumulative						Accumulated		Cumulative
	Cost		Amortization		Impairments		Net		Cost		Amortization		Impairments		Net
Finite-lived intangible assets:
Makena base technology	$	797,100	$	400,496	$	319,246	$	77,358	$	797,100	$	400,495	$	319,246	$	77,359
Makena auto-injector developed technology	79,100		9,206		—		69,894		79,100		6,952		—		72,148
Intrarosa developed technology	77,655		11,817		—		65,838		77,655		10,129		—		67,526
Total intangible assets	$	953,855	$	421,519	$	319,246	$	213,090	$	953,855	$	417,576	$	319,246	$	217,033

Schedule of expected future annual amortization expense related to intangible assets

We expect amortization expense related to our finite-lived intangible assets to be as follows (in thousands):

	Estimated
	Amortization
Period	Expense
Remainder of Year Ending December 31, 2019	$	41,329
Year Ending December 31, 2020	35,714
Year Ending December 31, 2021	30,016
Year Ending December 31, 2022	27,167
Year Ending December 31, 2023	18,046
Thereafter	60,818
Total	$	213,090

As of March 31, 2019, we determined that the ongoing supply issue with the Makena intramuscular (“IM”) products, which relates to the Makena base technology intangible asset was an indicator of potential impairment for that asset. As a result, we compared the projected undiscounted future cash flows for the Makena IM products and found that they exceeded the asset’s carrying value as of March 31, 2019. The evaluation of projected cash flows is dependent on management’s annual and ongoing forecasting, budgeting and planning processes and represents our best estimate of the future results of the Makena IM products as of a point in time. These estimates are subject to a number of assumptions. Actual results could differ materially from our assumptions in future periods and to the extent forecasted cash flows are lower in the future, an impairment charge could result.